Dosing of zoledronic acid throughout the treatment continuum in breast cancer

Peyman Hadji, Michael Gnant, Matti Aapro, Allan Lipton, Robert Coleman

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Several bisphosphonates including zoledronic acid (ZOL) are approved for treating bone metastases from breast cancer (BC). Recent trials demonstrated that ZOL prevents bone loss and reduces disease recurrence in early BC. This review uses pharmacodynamic, efficacy, and safety data from phase III trials of ZOL in early through metastatic BC to evaluate the dosing regimens used in each setting. The dosing frequencies of ZOL in early stage versus metastatic BC (4. mg 2-4 times per year versus monthly) are based on the respective levels of bone resorption and tumor burden. Data from ongoing clinical trials suggest that monthly dosing facilitates potential synergy between ZOL and chemotherapy in intermediate-risk BC and during neoadjuvant therapy. Overall, available data indicate that treatment with ZOL at appropriate intervals determined by disease characteristics helps attain key therapeutic goals in BC-maintaining skeletal integrity, reducing disease recurrence, and improving clinical outcomes.

Original languageEnglish (US)
Pages (from-to)175-188
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Issue number2
StatePublished - Aug 2011

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


Dive into the research topics of 'Dosing of zoledronic acid throughout the treatment continuum in breast cancer'. Together they form a unique fingerprint.

Cite this